Fosmidomycin + piperaquine combination therapy - Jomaa Pharma/Medicines for Malaria venture

Drug Profile

Fosmidomycin + piperaquine combination therapy - Jomaa Pharma/Medicines for Malaria venture

Alternative Names: Piperaquine + fosmidomycin combination therapy - Jomaa Pharma/Medicines for Malaria Venture

Latest Information Update: 03 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Jomaa Pharma; Justus Liebig University
  • Developer Jomaa Pharma
  • Class Organophosphorus compounds; Phosphonic acids; Quinolones; Small molecules
  • Mechanism of Action Oxidoreductase inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Malaria

Most Recent Events

  • 03 Mar 2017 Fosmidomycin + piperaquine combination therapy is still at phase II development stage for Malaria in Gabon (PO)
  • 03 Mar 2017 Fosmidomycin + piperaquine combination therapy - Jomaa Pharma/Medicines for Malaria venture is available for licensing as of 03 Mar 2017. www.jomaa-pharma.com
  • 14 Nov 2016 Jomaa Pharma completes a phase IIa trial in Malaria (In children, In adults) in Gabon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top